Molecular Designs Announces Acquisition of Lamda Biotech
Expanding the Product Portfolio and Market Reach
Molecular Designs, a leader in PCR assays, reagents, and equipment, has officially announced its acquisition of Lamda Biotech, a prominent provider of research products specializing in molecular biology, genomics, proteomics, and gene therapy. This acquisition will enable Molecular Designs to significantly expand its product portfolio, gain a stronger foothold in academic research and pharmaceutical markets, and enhance its team with highly skilled experts.
Lamda Biotech’s Legacy of Innovation
With over 20 years of industry leadership, Lamda Biotech is well-regarded for its cutting-edge PCR products, RT-PCR reagents, RT-qPCR kits, Direct-PCR genotyping kits, DNA ladders, SafeStain, and a wide array of tools for protein and cell biology research. The acquisition allows Molecular Designs to leverage its advanced manufacturing capabilities to scale Lamda’s innovative offerings. This growth will also facilitate faster research and development, and provide wider customer access through new distribution channels, all while maintaining a strong commitment to customer service excellence.
Leadership Perspective
Michael Clark, CEO of Molecular Designs, emphasized the importance of the acquisition, stating, “This acquisition marks a significant milestone for our company. By combining top-tier manufacturing with specialized product expertise, we are better positioned to meet the evolving needs of our clients.”
Strengthening Molecular Designs’ Leadership in Molecular Technology
The acquisition of Lamda Biotech cements Molecular Designs’ position as a key player in the molecular technology industry. It demonstrates a clear commitment to offering high-quality lab products and comprehensive research solutions, further solidifying its leadership within the scientific community.
About Molecular Designs
Molecular Designs, founded by physicians, is committed to simplifying access to affordable and easy-to-use molecular technologies. The company provides a range of multiplex PCR-based panels under GMP and ISO 13485:2016 standards for research use, along with complementary reagents and equipment to support cutting-edge research.
